Incidence and predictors of ophthalmic artery occlusion in intra-arterial chemotherapy for retinoblastoma.


Journal

Journal of neurointerventional surgery
ISSN: 1759-8486
Titre abrégé: J Neurointerv Surg
Pays: England
ID NLM: 101517079

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 13 08 2020
revised: 28 09 2020
accepted: 29 09 2020
pubmed: 31 10 2020
medline: 21 7 2021
entrez: 30 10 2020
Statut: ppublish

Résumé

Retinoblastoma is the most common primary intraocular malignancy in children. To determine the incidence of ophthalmic artery (OA) occlusion in patients treated with selective ophthalmic artery catheterization (OAC) for chemotherapy infusion for retinoblastoma. Also, to evaluate technical, anatomical, tumorous, and patient-related factors that are predictors of OA occlusion. A retrospective chart review was performed for patients diagnosed with intraocular retinoblastoma and managed with intra-arterial chemotherapy (IAC). The total study cohort included 208 retinoblastoma tumors of 208 eyes in 197 consecutive patients who underwent 688 attempted IAC infusions overall with a total of 624 successful OAC infusions. The total incidence of ophthalmic artery thrombosis was 11.1% (23/208). The numbers of successful OAC procedures before diagnosing OA occlusion were one OAC in six cases (27.3%), two in seven cases (31.8%), three in four cases (18.2%), four in one case (4.5%), five in two cases (9.1%), and six in one case (4.5%). Local factors relating to the chemotherapy and selective microcatheterization of the OA are essential factors in the development of OA thrombosis, as seen by the association of OA thrombosis with the frequency of IAC.

Sections du résumé

BACKGROUND BACKGROUND
Retinoblastoma is the most common primary intraocular malignancy in children.
OBJECTIVE OBJECTIVE
To determine the incidence of ophthalmic artery (OA) occlusion in patients treated with selective ophthalmic artery catheterization (OAC) for chemotherapy infusion for retinoblastoma. Also, to evaluate technical, anatomical, tumorous, and patient-related factors that are predictors of OA occlusion.
METHODS METHODS
A retrospective chart review was performed for patients diagnosed with intraocular retinoblastoma and managed with intra-arterial chemotherapy (IAC).
RESULTS RESULTS
The total study cohort included 208 retinoblastoma tumors of 208 eyes in 197 consecutive patients who underwent 688 attempted IAC infusions overall with a total of 624 successful OAC infusions. The total incidence of ophthalmic artery thrombosis was 11.1% (23/208). The numbers of successful OAC procedures before diagnosing OA occlusion were one OAC in six cases (27.3%), two in seven cases (31.8%), three in four cases (18.2%), four in one case (4.5%), five in two cases (9.1%), and six in one case (4.5%).
CONCLUSIONS CONCLUSIONS
Local factors relating to the chemotherapy and selective microcatheterization of the OA are essential factors in the development of OA thrombosis, as seen by the association of OA thrombosis with the frequency of IAC.

Identifiants

pubmed: 33122349
pii: neurintsurg-2020-016759
doi: 10.1136/neurintsurg-2020-016759
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

652-656

Informations de copyright

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: PJ is a consultant for Medtronic and MicroVention. SIT is a consultant for Stryker. The other authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.

Auteurs

Ahmad Sweid (A)

Department of Neurological Surgery, Thomas Jefferson University - Center City Campus, Philadelphia, Pennsylvania, USA.

Kareem El Naamani (K)

School of Medicine, Lebanese American University, Beirut, Beirut, Lebanon.

Kalyan Chekravarthy Sajja (KC)

Department of Neurosurgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Batoul Hammoud (B)

Department of Endocrinology, CHOP, Philadelphia, Pennsylvania, USA.

Michael D Knapp (MD)

Thomas Jefferson University Sidney Kimmel Medical College, Philadelphia, Pennsylvania, USA.

Daniel D Moylan (DD)

Thomas Jefferson University Sidney Kimmel Medical College, Philadelphia, Pennsylvania, USA.

Daniel Joffe (D)

Thomas Jefferson University Sidney Kimmel Medical College, Philadelphia, Pennsylvania, USA.

Charles E Morse (CE)

Thomas Jefferson University Sidney Kimmel Medical College, Philadelphia, Pennsylvania, USA.

Daniel Habbal (D)

Thomas Jefferson University Sidney Kimmel Medical College, Philadelphia, Pennsylvania, USA.

Joshua H Weinberg (JH)

Department of Neurological Surgery, Thomas Jefferson University - Center City Campus, Philadelphia, Pennsylvania, USA.

Stavropoula I Tjoumakaris (SI)

Department of Neurological Surgery, Thomas Jefferson University - Center City Campus, Philadelphia, Pennsylvania, USA.

Carol L Shields (CL)

Ocular Oncology Service, Wills Eye Hospital, Philadelphia, Pennsylvania, USA.

David A Lezama (DA)

Ocular Oncology Service, Wills Eye Hospital, Philadelphia, Pennsylvania, USA.
Instituto de Oftalmologia y Ciencias Visuales, Tecnologico de Monterrey, Monterrey, Mexico.

Li-Anne S Lim (LS)

Ocular Oncology Service, Wills Eye Hospital, Philadelphia, Pennsylvania, USA.

Lauren A Dalvin (LA)

Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.

Robert Rosenwasser (R)

Department of Neurosurgery, Thomas Jefferson University - Center City Campus, Philadelphia, Pennsylvania, USA.

Pascal Jabbour (P)

Department of Neurological Surgery, Thomas Jefferson University - Center City Campus, Philadelphia, Pennsylvania, USA pascal.jabbour@jefferson.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH